First AD

Second AD

Risk Stratification and Prognostic Markers in Castration-Sensitive Prostate Cancer 

Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?

What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions. 

Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer